ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Signatera
Resources related to Signatera residual disease testing from a simple drop of blood.
-
-
Dr. James Duke’s Head & Neck Cancer Story
Read Article
-
Ketch Study Data 1 Sheet
Read More
-
Anj’s Breast Cancer Story
Read Article
-
Using Circulating Tumor DNA–Based Molecular Residual Disease Detection for Postoperative Monitoring in Early-Stage Uterine Cancer
Ketch et al. JCO PO 2025
Read More
-
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients With Resected Stages I to III Colon Ca
Cohen et al. Annals of Surgery 2025
Read More
-
MRD Testing vs. Traditional Cancer Monitoring: What’s the Difference?
Read Article
-
Understanding Hereditary Cancer Risks in Ovarian Cancer
Read Article
-
How MRD Testing Helps Monitor Ovarian Cancer Recurrence
Read Article
-
Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing
Watch Video
-
Meet Anj, Breast Cancer Survivor and Signatera Patient
Watch Video
-
Post-Treatment H&N Cancer Surveillance with ctDNA
Read More
-
Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)
Honoré N, et al. ESMO 2025
Read More
-
Correlative Analysis of Tumor-Informed Circulating Tumor DNA (ctDNA) and the Survival Outcomes of Patients with Pancreatic Adenocarcinoma
Zhang Y, et al. Biomedicines. 2025
Read More
-
Feasibility of Personalized and Tumor-Informed Circulating Tumor DNA Assay for Early Recurrence Detection in Patients With Hepatocellular Ca
Abdelrahim M, et al. JCO Preci Oncol. 2025
Read More
-
Circulating Tumor DNA Detects Minimal Residual Disease in Patients with Locally Advanced Rectal Cancer After Total Neoadjuvant Therapy
Kim J, et al. Cancers 2025
Read More
-
Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcin
Zaanan et al. Nat Commun, 2025
Read More
-
Anal Cancer Sales Aid
Read More
-
Biliary Cancer Sales Aid
Read More
-
Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient
Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon
Watch Video
-
Loading More...
